Pharmacology of penile erection

Pharmacological Reviews

Volumn 53, Issue 3, 2001, Pages 417-450

  Andersson, K E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERMEDIN; APOMORPHINE; CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN; DOPAMINE; LINSIDOMINE; MOXISYLYTE; NITRIC OXIDE; NITRIC OXIDE DONOR; OXYTOCIN; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SEROTONIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS CAVERNOSUM; ERECTILE DYSFUNCTION; MALE; NEUROTRANSMISSION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RAT; REVIEW; SMOOTH MUSCLE; SPINAL REFLEX;

ANIMALS; HUMANS; IMPOTENCE; MALE; MUSCLE, SMOOTH; PENILE ERECTION; RATS; RISK FACTORS;

EID: 0034849563     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (531)

1. Endocrine consequences of long-term intrathecal administration of opioids
2. Is vasoactive intestinal polypeptide the principal transmitter involved in human penile erection?
3. Specific involvement of central 5-HT1A receptors in the mediation of male rat ejaculatory behavior
4. Effects of a new type of 5-HT receptor agonist on male rat sexual behavior
5. Calcitonin gene-related peptide: Immunohistochemical localization in, and effects on, the bovine penile artery
6. Immunohistochemical localization of peripheral nitric oxide synthase-containing nerves using antibodies raised against synthesized C-and N-terminal fragments of a cloned enzyme from rat brain
7. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys
8. Clinical pharmacology of potassium channel openers
9. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues
10. Pharmacology of erection: Agents which initiate and terminate erection
11. The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat
12. Neurotransmission, contraction and relaxation of penile erectile tissues
13. Physiology of penile erection
14. Rationale for the combination of PGE(1) and S-nitroso-glutathione to induce relaxation of human penile smooth muscle
15. Oxytocin stimulation of penile erection. Pharmacology, site, and mechanism of action
16. Nitric oxide is a central mediator of penile erection
17. Neuromodulation of penile erection: An overview of the role of neurotransmitters and neuropeptides
18. Oxytocin: An extremely potent inducer of penile erection and yawning in male rats
19. Paraventricular nucleus lesion prevents yawning and penile erection induced by apomorphine and oxytocin, but not ACTH
20. Acth- and alpha-MSHinduced grooming, stretching, yawning and penile erection in male rats: Site of action in the brain and role of melanocortin receptors
21. 8 -vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH
22. Omega-conotoxin prevents apomorphine and oxytocin-induced penile erection and yawning in male rats
23. Oxytocin-induced penile erection and yawning: Role of calcium and prostaglandins
24. Possible role for endothelins in penile erection
25. Vesicular acetylcholine transporter (VAChT) protein: A novel and unique marker for cholinergic neurons in the central and peripheral nervous systems
26. Utilisation prolongée de chlorhydrate de moxisylyte (Icavex) en auto-injections intra-caverneuses dans le traitement de l'impuissance
27. Identification of a down-regulated mRNA transcript in corpus cavernosum from diabetic patients with erectile dysfunction
28. Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model
29. Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction
30. Effects of intracavernosal trazodone hydrochloride: Animal and human studies
31. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle
32. Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle
33. Study of the etiologic relationship of arterial atherosclerosis to corporal veno-occlusive dysfunction in the rabbit
34. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
35. Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase enhances nitric oxide-dependent relaxation of rabbit corpus cavernosum
36. 5-Hydroxytryptamine 2C receptors on spinal neurons controlling penile erection in the rat
37. A review of central 5-HT receptors and their function
38. Katp channels gated by intracellular nucleotides and phospholipids
39. Dose dependent D2 effects on genital reflexes after MPOA injections of quinelorane and apomorphine
40. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
41. Oral phentolamine as treatment for erectile dysfunction
42. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence
43. Systemic and cavernous plasma levels of endothelin 1 in healthy males during different functional conditions of the penis
44. Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection
45. Drug-induced penile erections in rats: Indications of serotonin1B receptor mediation
46. Depletion of brain serotonin differently affects behaviors induced by 5HT1A, 5HT1C, and 5HT2 receptor activation in rats
47. Opiate-androgen interactions in drug-induced yawning and penile erections in the rat
48. Involvement of 5-HT1Creceptors in drug-induced penile erections in rats
49. The density and distribution of endothelin 1 and endothelin receptor subtypes in normal and diabetic rat corpus cavernosum
50. Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats
51. Intracavernosal (IC) injection of a potassium channel opener to treat erectile dysfunction
52. Inositol trisphosphate, a novel second messenger in cellular signal transduction
53. Behavioral effects of ACTH and MSH peptides
54. Penile erection and ejaculation: A central effect of ACTH-like peptides in mammals
55. Effects of opioid blockade with nalmefene in older impotent men
56. Pharmacotherapy for erectile dysfunction
57. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4)
58. Pharmacological analysis of male rat sexual behavior
59. Evidence of an incertohypothalamic dopamine neuron system in the rat
60. Characterization of trazodone-associated priapism
61. Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum
62. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
63. Sildenafil, a novel oral therapy for male erectile dysfunction
64. B receptor site distribution in the rat central nervous system
65. Localization of nitric oxide synthase indicating a neural role for nitric oxide
66. Effects of an environmental anti-androgen on erectile function in an animal penile erection model
67. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis
68. Human connexin43 gap junction channel gating: Evidence for mode shifts and/or heterogeneity
69. Melatonin enhances sexual behavior in the male rat
70. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Pathways to the limbic system, medulla oblongata and spinal cord
71. Nitric oxide in the penis: Physiology and pathology
72. Oral pharmacotherapy for erectile dysfunction: Current perspectives
73. Nitric oxide: A physiologic mediator of penile erection
74. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase
75. Localization of nitric oxide synthase in spinal nuclei innervating pelvic ganglia
76. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis
77. Reduced rate of fibrotic nodules in the cavernous bodies following auto-intracavernous injections of moxisylyte compared to papaverine
78. 1
79. Safety of intracavernous injections using an alpha-blocking agent
80. Forskolin: A promising new adjunct to intracavernous pharmacotherapy
81. Pharmacology of nociceptin and its receptor: A novel therapeutic target
82. Gap junctions formed of connexin43 interconnect smooth muscle cells of the human corpus cavernosum
83. Effectiveness of yohimbine in the treatment of erectile disorder: Four meta-analytic integrations
84. Plasma oxytocin increases in the human sexual response
85. Age decreases nitric oxide synthase-containing nerve fibers in the rat penis
86. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog
87. Oxytocin and sexual behavior
88. Impairment of corpus cavernosal smooth muscle relaxation by glycosylated human haemoglobin
89. Endothelial and neuronal-derived nitric oxide mediated relaxation of corpus cavernosal smooth muscle in a rat, in vitro, model of erectile function
90. Minoxidil versus nitroglycerin: A prospective double blind controlled trial in transcutanous erection facilitation for organic impotence
91. Minoxidil versus nitroglycerine: A prospective, double blind, controlled trial in transcutaneous therapy for organic impotence
92. Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: A comparison with other species
93. Regulation of actomyosin and contraction in smooth muscle
94. Apomorphine, deprenyl, and yohimbine fail to increase sexual behavior in rhesus males
95. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat
96. Nociceptin, a novel endogenous ligand for the ORL1 receptor, has potent erectile activity in the cat
97. Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the feline erection model
98. Adrenomedullin induces penile erection in the cat
99. Alpha2-adrenergic and opiate receptor blockade
100. Yohimbine induced anxiety and increased noradrenergic function in humans: Effects of diazepam and clonidine
101. Assessment of alpha2-adrenergic autoregulator function in humans: Effects of oral yohimbine
102. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway
103. Evaluation of oral Ro 70-0004/003, an alpha1A adrenoceptor antagonist, in the treatment of male erectile dysfunction
104. The penis as a vascular organ: The importance of corporal smooth muscle tone in the control of erection
105. The "syncytial tissue triad": A model for understanding how gap junctions participate in the local control of penile erection
106. Gap junctions and ion channels: Relevance to erectile dysfunction
107. Analysis of the presence and physiological relevance of subconducting states of connexin43-derived gap junction channels in cultured human corporal vascular smooth muscle cells
108. The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle
109. Endothelin-1 as a putative modulator of erectile dysfunction: I. Characteristics of contraction of isolated corporal tissue strips
110. Pharmacological studies of human erectile tissue: Characteristics of spontaneous contractions and alterations in α-adrenoceptor responsiveness with age and disease in isolated tissues
111. 2+ in cultured human corporal smooth muscle cells
112. Integrative erectile biology: The role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection
113. Gap junctions in vascular tissues: Evaluating the role of intercellular communication to the modulation of vasomotor tone
114. Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men
115. Kinetic characteristics of α-adrenergic contractions in human corpus cavernosum smooth muscle
116. Kinetic studies of contraction in human erectile tissue (HET) and rabbit aortic rings in vitro: Modulation by papaverine and the dihydropyridine analog nifedipine
117. Ion channels and gap junctions: Their role in erectile physiology, dysfunction, and future therapy
118. Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMPdependent relaxation in rabbit corpus cavernosum smooth muscle in vitro
119. Transcutaneous nitroglycerin therapy in the treatment of impotence
120. Central alpha-2-adrenoceptors modulate male rat sexual activity
121. Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats
122. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
123. Effect of angiotensin II on corpus cavernosum smooth muscle in relation to notric oxide environment: In vitro studies in canines
124. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
125. Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum
126. Human calcitonin gene-related peptide activates adenylate cyclase and releases prostacyclin from human umbilical vein endothelial cells
127. Methadone dose and human sexual behavior
128. Sexual behavior in heroin addiction and methadone maintenance. Correlation with plasma luteinizing hormone
129. mRNA and protein expression of nitric oxide synthase and adrenoceptor alpha 1 in young and old rat penile tissues
130. Receptor-specific influence of endothelin-1 in the erectile response of the rat
131. Autonomic innervation of male reproductive genitalia
132. Neural and endothelial nitric oxide synthase activity in rat penile erectile tissue
133. Denervation-induced changes in perineuronal plexuses in the major pelvic ganglion of the rat: Immunohistochemistry for vasoactive intestinal polypeptide and tyrosine hydroxylase and histochemistry for NADPH-diaphorase
134. Prostanoid production in rabbit corpus cavernosum: I. Regulation by oxygen tension
135. Prostanoid production in rabbit corpus cavernosum: II. Inhibition by oxidative stress
136. Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies
137. Assessment of erectogenic properties of apomorphine and yohimbine in man
138. Patterns of messenger RNA expression for alpha1-adrenoceptor subtypes in human corpus cavernosum
139. 1L-adrenoceptor mediates contraction in human erectile tissue
140. Neural control of penile erection
141. Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence
142. Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum
143. The effect of papaverine on arterial and venous hemodynamics of erection
144. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents
145. Expression of myosin isoforms in smooth muscle cells in the corpus cavernosum penis
146. Follow-up results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction
147. Effects of naloxone on penile erection in cats
148. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
149. Acute low doses of melatonin stimulate rat sex behavior: The role of serotonin neurotransmission
150. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
151. Nitric oxide synthase immunoreactivity in the rat, mouse, cat and squirrel monkey spinal cord
152. Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation
153. Diabetes mellitus increases nitric oxide synthase in penises but not in major pelvic ganglia of the rat
154. Concentrations of GABA and glycine in discrete brain nuclei. Stress-induced changes in the levels of inhibitory amino acids
155. Neuronal nitric oxide synthase alternatively spliced forms: Prominent functional localizations in the brain
156. Trazodone a double blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings
157. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials
158. Repeated PGE1 treatment enhances nitric oxide and erection responses to nerve stimulation in the rat penis by upregulating constitutive NOS isoforms
159. Endorphins in male impotence: Evidence for naltrexone stimulation of erectile activity in patient therapy
160. Transmitter role of vasoactive intestinal peptide
161. Ca) channel in cultured human corporal smooth muscle cells
162. A stretch-sensitive Cl- channel in human corpus cavernosal myocytes
163. Molecular cloning and characterization of a distinct human phosphodiesterase gene family; PDE11A
164. Cellular and non-cellular metabolism of organic nitrates to nitric oxide: Involvement of enzymic and non-enzymic pathways
165. Comparison of the effects of different isomers of bicuculline infused in the preoptic area on male rat sexual behavior
166. GABAergic control of masculine sexual behavior
167. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase
168. The endothelial nitric-oxide synthase-caveolin regulatory cycle
169. Behavioural effects induced by intracisternally injected ACTH and MSH
170. IP3 receptors. Ligand-activated calcium channels in multiple forms
171. Studies on the mechanisms involved in the ATP-induced relaxation in human and rabbit corpus cavernosum
172. Effects of 5,7-dihydroxytryptamine on serotonin 1 and 2 receptors throughout the rat central nervous system using quantitative autoradiography
173. Effects of D2 dopaminergic receptor stimulation on male rat sexual behavior
174. Effects of some calcium channel blockers on isolated human penile erectile tissue
175. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction
176. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects
177. Mechanism of YC-1-induced activation of soluble guanylyl cyclase
178. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets
179. Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers
180. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens
181. In vivo and in vitro investigation of the effects of sildenafil on rat cavernous smooth muscle
182. Trazodone hydrochloride: A wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology
183. Functional characteristics of heterologously expressed 5-HT receptors
184. Intracavernous selfinjection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure
185. Proerectile effects of apomorphine delivered at the spinal level in anesthetized rat
186. Spinal proerectile effect of apomorphine in the anesthetized rat
187. Daily and on-demand IC351 treatment of erectile dysfunction
188. Central neural regulation of penile erection
189. Central noradrenergic control of penile erection
190. Neural control of penile erection
191. Stimulation of the medial preoptic area of the hypothalamus in the rat elicits increases in intracavernous pressure
192. The peripheral pharmacology of erection
193. Metabolism of prostaglandins A and E1 in man
194. Characterization of alpha-adrenoceptor subtypes in the corpus cavernosum of patients undergoing sex change surgery
195. 2-adrenoceptor
196. Evidence against involvement of endorphine in sexual arousal and orgasm in man
197. Oral phentolamine: An alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction
198. Erectile function and naltrexone
199. Vasomax for the treatment of male erectile dysfunction
200. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves
201. Nitric oxide and the cyclic GMP system in the penis
202. Oral therapy with phentolamine in chronic congestive heart failure
203. New treatments for erectile impotence
204. Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men
205. Clinical experience with intraurethral alprostadil (MUSER) in the treatment of men with erectile dysfunction. A retrospective study
206. Oral phentolamine in non-specific erectile insufficency
207. Erectile dysfunction in aging: Upregulation of endothelial nitric oxide synthase
208. Vasoactive intestinal polypeptide and norepinephrine concentration in the corpora cavernosa of impotent men
209. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
210. Systemic pharmacokinetics of papaverine and phentolamine: Comparison of intravenous and intracavernous application
211. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders
212. Neuroeffector transmission to different layers of smooth muscle in the rat penile bulb
213. Pilot study on systemic plasma concentrations of prostaglandin E1, 15-keto PGEO and PGEO after intravenous injection in patients with chronic erectile dysfunction
214. Neuropeptides in the human penis: An immunohistochemical study
215. Pituitary adenylate cyclases activating peptide (PACAP), helospectin, peptide histidine methionine, and vasoactive intestinal polypeptide (VIP) in the human penis: An immunocytochemical evaluation on the occurrence of VIPrelated peptides
216. Effects of lesions in the hypothalamic paraventricular, supraoptic and suprachiasmatic nuclei on vasopressin and oxytocin in rat brain and spinal cord
217. Neurogenic nitric oxide mediates relaxation of canine corpus cavernosum
218. Proerectile effects of novel serotonin agonists
219. Synthetic nitrovasodilators are effective, in vitro, in relaxing penile tissue from impotent men: The findings and their implications
220. Apomorphine an update of clinical trial results
221. Central neuropharmacological agents and mechanisms in erectile dysfunction: The role of dopamine
222. A therapeutic taxonomy of treatments for erectile dysfunction: An evolutionary imperative
223. Effects of castration and exogenous testosterone supplementation in an animal model of penile erection
224. Recovery of erectile function by the oral administration of apomorphine
225. NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum
226. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum
227. Localization and effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in human penile erectile tissue
228. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice
229. Distribution and function of nitric oxide-containing nerves in canine corpus cavernosum and spongiosum
230. Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase
231. A double blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil
232. Non-synergistic relaxant effects of vasoactive intestinal polypeptide and SIN-1 in human isolated cavernous artery and corpus cavernosum
233. The orphan opioid receptor and its endogenous ligand - Nociceptin/orphanin FQ
234. Cloning and characterization of two splice variants of human phosphodiesterase 11A
235. International Union of Pharmacology. X. Recommendation for nomenclature of a1-adrenoceptors: Consensus update
236. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists
237. Actions of endothelin on isolated corpus cavernosum from rabbit and man
238. Functional effects, binding sites and immunolocalization of endothelin-1 in isolated penile tissues from man and rabbit
239. Phospholipase C activation by endothelin-1 and noradrenaline in isolated penile erectile tissue from rabbit
240. Targeted disruption of the neuronal nitric oxide synthase gene
241. Selective effects of beta-endorphin infused into the hypothalamus, preoptic area and bed nucleus of the stria terminalis on the sexual and ingestive behavior of male rats
242. Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: Implications for copulation
243. Brain localization of cholinergic influence on male sex behavior in rats: Antagonists
244. Brain localization of cholinergic influence on male sex behavior in rats: Agonists
245. Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue
246. Human pharmacology of orally administered phentolamine
247. Fluoxetin-induced sexual dysfunction and an open trial of yohimbine
248. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro
249. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study
250. Pharmacotherapy of impotence: Where are we going?
251. Pharmacotherapy of erectile dysfunction: A review
252. Hemodynamics of papaverine- and phentolamine-induced penile erection
253. Male sexual arousal with repeated exposure to erotic stimuli
254. Intracavernosal endothelin levels of impotent men before and after papaverine induced penile erection
255. Sexuality and impotence in the aging man
256. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction
257. Calcium movements, distribution, and functions in smooth muscle
258. The role of prostaglandins in the aetiology and treatment of erectile dysfunction
259. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents
260. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum
261. Endothelin-1-induced modulation of contractile responses elicited by an alpha 1-adrenergic agonist on human corpus cavernosum smooth cells
262. Modulation of vasoactive intestinal polypeptide (VIP)-mediated relaxation by nitric oxide and prostanoids in the rabbit corpus cavernosum
263. Presence and biological activity of C-type natriuretic peptide-dependent guanylate cyclase-coupled receptor in the penile corpus cavernosum
264. Vasoactive intestinal polypeptide (VIP) and peptide histidine methionine (PHM) in human penile corpus cavernosum tissue and circumflex veins: Localization and in vitro effects
265. Comparison of the papaverine effects on isolated human penile circumflex veins and corpus cavernosum
266. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma
267. Suppression of the excitatory adrenergic neurotransmission; a possible role of cholinergic nerves in the retractor penis muscle
268. Soluble guanylate cyclase and cGMP-dependent protein kinase I expression in the human corpus cavernosum
269. p-Chlorophenylalanine facilitates copulatory behavior in septal lesioned but not in preoptic lesioned male rats
270. Affinity of trazodone for human penile alpha1- and alpha2-adrenoceptors
271. Effect of vasoactive intestinal peptide in man
272. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double blind crossover study
273. Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis
274. Molecular biological characterization of phosphodiesterase 3A from human corpus cavernosum
275. Expression of different phosphodiesterase genes in human cavernous smooth muscle
276. Physiological features of visceral smooth muscle cells, with special reference to receptors and ion channels
277. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects
278. Apomorphine-induced penile tumescence in impotent patients-preliminary findings
279. Apomorphine: Clinical studies on erectile impotence and yawning
280. Oral trazodone as empirical therapy for erectile dysfunction: A retrospective review
281. Effect of lesions in the paraventricular nucleus of the hypothalamus on vasopressin and oxytocin content in the brainstem and spinal cord of rat
282. Interaction of aminoalkylcarbamates of forskolin with adenylyl cyclase: Synthesis of an iodinated derivative of forskolin with high affinity for adenylyl cyclase
283. Characterization of ATP-sensitive potassium channels in human corporal smooth muscle cells
284. Prostaglandin E1 activates the large-conductance KCa channel in human corporal smooth muscle cells
285. Human recombinant soluble guanylyl cyclase: Expression, purification, and regulation
286. Effects of intrathecal administration of 8-OH-DPAT on genital reflexes and mating behavior in male rats
287. Adrenergic alpha-receptors outnumber beta-receptors in human penile corpus cavernosum
288. Non-surgical management of erectile dysfunction
289. Efficacy of apomorphine SL vs placebo for erectile dysfunction in patients with hypertension
290. Expression of three isoforms of cGMPbinding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum
291. Role of cyclic adenosine monophosphate in prostaglandin E1-induced penile erection in rabbits
292. Changes in the VIPergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males
293. Selective histochemical demonstation of dopamine terminal systems in rat di- and telencephalon: New evidence for dopaminergic innervation of hypothalamic neurosecretory nuclei
294. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
295. Serotonergic projections from the ventral medulla to the intermediolateral cell column in the rat
296. Guanylyl cyclases and signaling by cyclic GMP
297. Comparison of oral and intracavernosal vasoactive agents in penile erection
298. Erectile dysfunction
299. Cavernosal nerve stimulation in the rat reverses castration-induced decrease in penile NOS activity
300. Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide
301. Septohippocampal cholinergic pathway and penile erections induced by dopaminergic and cholinergic stimulants
302. Role of the dopaminergic, serotonergic and cholinergic link in the expression of penile erection in rats
303. Possible involvement of the septohippocampal cholinergic and raphe-hippocampal serotonergic activations in the penile erection induced by fenfluramine in rats
304. Cloning of a novel neuronal nitric oxide synthase expressed in penis and lower urinary tract
305. Erectile dysfunction: From biochemical pharmacology to advances in medical therapy
306. Anatomical distribuion and ultrastructural organization of the GABAergic system in the rat spinal cord. An immunocytochemical study using anti-GABA antibodies
307. Vasoactive intestinal peptide and impotence in experimental diabetes mellitus
308. Common precursor to the corticotropins and endorphins
309. Cigarette smoking: An independent risk factor for impotence?
310. The potent relaxant effect of adenosine in rabbit corpora cavernosa is nitric oxide independent and mediated by A2 receptors
311. Autoradiographic mapping of 5-HT1, 5-HT1A, 5-HT1B and 5-HT2 receptors in the rat spinal cord
312. Moxisylyte: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence
313. A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes
314. Preliminary results of a comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction
315. Prospective comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction
316. Stimulation of spinal serotonergic receptors facilitates seminal emission and suppresses penile erectile reflexes
317. Effects of intrathecal and systemic administration of buspirone on genital reflexes and mating behavior in male rats
318. Pyrimidine and triazine 3-oxide sulfates: A new family of vasodilators
319. Brain monoaminergic control of male reproductive behavior. I. Serotonin and the postejaculatory period
320. Effects of morphine, β-endorphin and naloxone on catecholamine levels and sexual behavior in the male rat
321. Central nervous system pathways involved in the control of penile erection
322. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction
323. Trazodone, a double blind trial for treatment of erectile dysfunction
324. Nitric oxide synthase inhibitors prevent apomorphine-and oxytocin-induced penile erection and yawning in male rats
325. Nitric oxide donors induce penile erection and yawning when injected in the central nervous system of male rats
326. Role of central nitric oxide in the control of penile erection and yawning
327. Apomorphine-induced penile erection and yawning: Site of action in the brain
328. Evidence that apomorphine induces penile erection and yawning by releasing oxytocin in the central nervous system
329. Apomorphine- and oxytocin-induced penile erection and yawning in intact and castrated male rats: Effects of sexual steroids
330. Effect of excitatory amino acid receptor antagonists on apomorphine-, oxytocin-and ACTH-induced penile erection and yawning in male rats
331. Penile erection and yawning induced by paraventricular NMDA injection in male rats are mediated by oxytocin
332. G-nitro-Larginine methyl ester or apomorphine- and oxytocin-induced penile erection and yawning: Site of action in the brain
333. Nitric oxide synthase inhibitors prevent N-methyl-D-aspartic acid-induced penile erection and yawning in male rats
334. Prevention by morphine of apomorphine- and oxytocin-induced penile erection: Site of action in the brain
335. Prevention by morphine of N-methyl-D-aspartic acid-induced penile erection and yawning: Involvement of nitric oxide
336. Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: Involvement of nitric oxide
337. N-methyl-D-aspartic acidinduced penile erection and yawning: Role of hypothalamic paraventricular nitric oxide
338. Oxytocin increases nitric oxide production in the paraventricular nucleus of the hypothalamus of male rats: Correlation with penile erection and yawning
339. Nitric oxide production is increased in the paraventricular nucleus of the hypothalamus of male rats during non-contact penile erections and copulation
340. Morphine injected into the paraventricular nucleus of the hypothalamus prevents noncontact penile erections and impairs copulation: Involvement of nitric oxide
341. The epidemiology and pathophysiology of erectile dysfunction
342. Effects of IC351 on erectile response to visual sexual stimulation
343. Non-invasive management of impotence with transcutaneous nitroglycerin
344. 5-HT2C receptors mediate penile erections in rats: Actions of novel and selective agonists and antagonists
345. Eicosanoids, erections and erectile dysfunction
346. Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: An in vitro study
347. Androgenic maintenance of the erectile response in the rat
348. The role of androgens in the erectile response: A 1999 perspective
349. Androgenic maintenance of inflow and veno-occlusion during erection in the rat
350. The loss of alpha-adrenergic effect during the erectile response in the long-term diabetic rat
351. The role of prostaglandins in penile erection
352. Opiate use and sexual function
353. Morphological and functional in vitro and in vivo characterzation of the mouse corpus cavernosum
354. Drugs affecting dopamine neurons and yawning behaviour
355. Noradrenaline release in human corpus cavernosum and its modulation via presynaptic alpha 2-adrenoceptors
356. Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors
357. 3H]hydroxytryptamine binding sites in the rat spinal cord tissue
358. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs
359. Effect of yohimbine-trazodone on psychogenic impotence: A randomized, double blind, placebo-controlled study
360. Developmental status of topical therapies for erectile and ejaculatory dysfunction
361. Yohimbine in erectile dysfunction: The facts
362. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial
363. Oral and topical treatment of erectile dysfunction. Present and future
364. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor
365. Sildenafil: A novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
366. The biochemical and neurologic basis for the treatment of male erectile dysfunction
367. The role of prostaglandin E as determined by expression of functional prostaglandin E receptors in human corpus cavernosum
368. 1 in human corpus cavernosum smooth muscle
369. Gap junctional communication between human corpus cavernosum smooth muscle cells in culture: Gating behavior and single channel events
370. Intracavernosal forskolin: Role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy
371. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators
372. 1-adrenoceptors
373. Changes in oxytocin and vasopressin secretion during sexual activity in men
374. Prostanoid receptors: Structures, properties, and functions
375. Impotence
376. Multiple types of ion channels in cavernous smooth muscle
377. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs
378. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor DA-8159
379. The pharmacokinetics of yohimbine in man
380. Topical nitroglycerin: A potential treatment for impotence
381. Efficacy and safety of apomorphine SL vs placebo for meale erectile dysfunction (MED)
382. Treatment of men with erectile dysfunction with transurethral alprostadil
383. Effect of infused vasoactive intestinal peptide on airway function in normal subjects
384. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells
385. Serotonin and sexual behavior in the male rabbit
386. Renin angiotensin system in rabbit corpus cavernosum: Functional characterization of angiotensin II receptors
387. The endothelin ET(B) receptor agonist
388. Functional characterization of endothelin receptors in the bovine retractor penis muscle and penile artery
389. Sexual aspects of drug abuse in narcotic addicts
390. Apomorphine and haloperidol, but not domperidone, affect penile reflexes in rats
391. The effects of intracranial administration of the dopamine agonist apomorphine on penile reflexes and seminal emission in the rat
392. The effects of intrathecal administration of the dopamine agonist apomorphine on penile reflexes and copulation in the male rat
393. Microinjection of cis-flupenthixol, a dopamine antagonist, into the medial preoptic area impairs sexual behavior of male rats
394. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat
395. Differences in the actions of calcitonin gene-related peptide (CGRP) in pig detrusor and vesical arterial smooth muscle
396. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations
397. Opioids and sexual behaviour
398. Defective smooth muscle regulation in cGMP kinase I-deficient mice
399. Evidence against vasoactive intestinal polypeptide as the relaxant neurotransmitter in human cavernosal smooth muscle
400. Cloning of human prostanoid receptors
401. Diabetic rats are unresponsive to the penile erection-inducing effect of intracerebroventricularly injected adrenocorticotropin
402. Nitric oxide is involved in the ACTH-induced behavioral syndrome
403. Cyclic nucleotide phosphodiesterases and vascular smooth muscle
404. Quinelorane (LY 163502), a D2 dopamine receptor agonist, acts centrally to facilitate penile erections of male rhesus monkeys
405. Serotonergic influences on male sexual behavior of rhesus monkeys: Effects of serotonin agonists
406. Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure for erectile failure: A diagnostic comparative study of 40 patients
407. A rational for prostaglandin E1 in erectile failure: A survey of worldwide experience
408. Three cases of manic symptoms following yohimbine administration
409. 1 adrenergic receptor subtype mRNA expression in human corpus cavernosum
410. Ex vivo expression of nitric oxide synthase isoforms (eNOS/iNOS) and calmodulin in human penile cavernosal cells
411. Spinal control of penile erection
412. Molsidomine
413. Diminished neurogenic but not pharmacological erections in the 2-to 3-month experimentally diabetic F-344 rat
414. Modification of sexual behavior of Long-Evans male rats by drugs acting on the 5-HT1A receptor
415. Double blind trial of yohimbine in treatment of psychogenic impotence
416. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway
417. Androgens modulate the α-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum
418. Comparison of transdermal nitroglycerin and intracavernous injection of papaverine in the treatment of erectile dysfunction in patients with spinal cord injuries
419. Direct immunocytochemical localization of 5-hydroxytryptamine receptors in the adult rat spinal cord: A light and electron microscopic study using an anti-idiotypic antiserum
420. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy
421. Activation of gamma-aminobutyric acid(A) receptors in the paraventricular nucleus of the hypothalamus reduces apomorphine-, N-methyl-D-aspartic acid-and oxytocin-induced penile erection and yawning in male rats
422. Clinical pharmacokinetics of molsidomine
423. N-3-substituted imidazoquinazolinones potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction
424. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection
425. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age
426. Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal
427. Endothelin: Localization, synthesis, activity, and receptor types in human penile corpus cavernosum
428. Diabetic penile neuropathy
429. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence
430. Pathophysiology of prolonged penile erection associated with trazodone use
431. Rat spinal cord neurons contain nitric oxide synthase
432. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptideand phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenicerectile dysfunction
433. The effects of alterations in nitric oxide levels in the paraventricular nucleus on copulatory behavior and reflexive erections in male rats
434. Effect of the nitric oxide level in the medial preoptic area on male copulatory behavior in rats
435. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat
436. Systemic or intracranial apomorphine increases copulation in long-term castrated male rats
437. Localization of androgen receptor in nitric oxide synthase- and vasoactive intestinal peptide-containing neurons of the major pelvic ganglion innervating the rat penis
438. Hemodynamic improvement following single dose of oral phentolamine. Administration in patients with chronic low output cardiac failure
439. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS
440. Effect of apomorphine on penile tumescence in men with psychogenic impotence
441. Molecular studies of connexin43 (Cx43) expression in isolated corporal tissue strips and cultured corporal smooth muscle cells
442. Stimulation of P2y purinoceptors induces, via nitric oxide production, endothelium-dependent relaxation of human isolated corpus cavernosum
443. New insights into dopaminergic receptor function using antisense and genetically altered animals
444. Adrenoceptor-mediated regulation of the contractility in horse penile resistance arteries
445. Prejunctional alpha 2-adrenoceptors inhibit nitrergic neurotransmission in horse penile resistance arteries
446. Effects of intracavernous administration of selective antagonists of alpha(1)-adrenoceptor subtypes on erection in anesthetized rats and dogs
447. Topographic principles in the spinal projections of serotonergic and non-serotonergic brainstem neurons in the rat
448. Origin and termination of the diencephalo-spinal dopamine system in the rat
449. Organization of diencephalic dopamine neurons projecting to the spinal cord of the rat
450. Nitric oxide and neurons
451. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
452. Signal transduction and regulation in smooth muscle
453. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II
454. Transcutaneous nitroglycerin in the treatment of erectile dysfunction in spinal cord injured
455. Immunocytochemical distribution of endothelial nitric oxide synthase (eNOS) in human corpus cavernosum
456. Apomorphine- and oxytocin-induced penile erection and yawning in male rats: Effect of pertussis toxin
457. On the putative mechanistic basis for intraoperative propofol-induced penile erections
458. Erectile response on visual sexual stimulation after 20 mg or 40 mg BAY 38-9456 or placebo
459. Viagra-after one year
460. Neural pathways and central sites involved in penile erection: Neuroanatomy and clinical implications
461. Effects of m-clorophenylpiperazine on penile and bladder function in rats
462. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals
463. Signal transduction in cavernous smooth muscle
464. A possible role for calcitonin-gene-related peptide in the regulation of the smooth muscle tone of the bladder and penis
465. Preliminary report on the effect of the nitric oxide (NO) donor SIN-1 on human cavernous tissue in vivo
466. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction
467. Calcitonin-gene-related peptide: A possible role in human penile erection and its therapeutical application in impotent patients
468. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo
469. Different effects of omega-conotoxin on penile erection, yawning and paraventricular nitric oxide in male rats
470. Effect of vasoactive intestinal peptide and acetylcholine on penile erection in the rat in vivo
471. Autoradiographic localization of nitric oxide synthase binding sites in normal and diabetic rat corpus cavernosum
472. Effect of yohimbine hydrochloride on erectile impotence: A double blind study
473. Spinal monoaminergic modulation of masculine copulatory behavior in the rat
474. The paraventricular nucleus of the hypothalamus: Cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods
475. Dopamine-stimulated sexual behavior is testosterone dependent in mice
476. Effects of fenfluramine, mchlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in nonhuman primates
477. Effects of adenosine triphosphate on canine penile erection
478. Effects of adenosine on canine penile erection
479. Transdermal nitrate, penile erection and spousal headache
480. Coexistence of nitric oxide synthase, tyrosin hydroxylase and vasoactive intestinal polypeptide in human penile tissue- a triple histochemical and immunohistochemical study
481. Localization of NADPH diaphorase and vasoactive intestinal polypeptide-containing neurons in the efferent pathway to the rat corpus cavernosum
482. Spinal and brain circuits to motoneurons of the bulbospongiosus muscle: Retrograde transneuronal tracing with rabies virus
483. Oxytocinergic and serotonergic innervation of identified lumbosacral nuclei controlling penile erection in the male rat
484. Effects of a novel phosphodiesterase type 5 inhibitor, sildenafil, on methacholine induced relaxation of isolated rabbit corpus cavernosum
485. Effect of intracavernosal sodium nitroprusside in impotence
486. Oxytocin-immunoreactive terminals synapse on oxytocinergic neurons in the supraoptic nuclei
487. Autoradiographic localization of 5-hydroxytryptaminelA, 5-hydroxytryptaminelB and 5-hydroxytryptaminelC/2 binding sites in the rat spinal cord
488. Correlations of purinergic, cholinergic and adrenergic functions in rabbit corporal cavernosal tissue
489. Detection of m2 muscarinic acetylcholine receptor mRNA in human corpus cavernosum by in-situ hybridization
490. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms
491. 1-adrenergic receptor subtypes in human corpus cavernous tissue and in cultured trabecular smooth muscle cells
492. G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells
493. Expression of functional alpha2-adrenergic receptor subtypes in human copus cavernosum and in cultured trabecular smooth muscle cells
494. 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine
495. Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells
496. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction
497. Intracavernous calcitonin gene-related peptide plus prostaglandin E1: Possible alternative to penile implants in selected patients
498. Different distribution of caveolin-1 and caveolin-3in the hunman corpus cavernosum: Immunohistochemical study, in comparison with nitric oxide synthase nerve and low affinity nerve growth factor receptor
499. The transdermal route in the treatment of male sexual impotence: Preliminary data on the use of yohimbine
500. Opiate antagonist in erectile dysfunction: A possible new treatment option? Results of a pilot study with naltrexone
501. NADPH diaphorase in the spinal cord of rats
502. Nitric oxide-synthesizing neurons originating at several different levels innervate rat penis
503. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction
504. Oxytocinergic innervation of autonomic nuclei controlling penile erection in the rat
505. Differential influence of a selective melanocortin MC4 receptor antagonist (HSO14) on melanocortin-induced behavioral effects in rats
506. Hypersexuality - A complication of dopaminergic therapy in Parkinson's disease
507. Double blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction
508. Vasoactive intestinal peptide facilitates normal erection
509. Comparative studies of the maxi-K (K(Ca)) channel in freshly isolated myocytes of human and rat corpora
510. Microinjection of the dopamine antagonist cis-flupenthixol into the MPOA impairs copulation, penile reflexes and sexual motivation in male rats
511. Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction
512. Effect of phentolamine on venous return in human erection
513. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double blind, placebo controlled crossover study
514. Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II
515. Melanocortin receptors: Perspectives for novel drugs
516. New aspects on the melanocortins and their receptors
517. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers
518. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase
519. Effects of purines on rabbit corpus cavernosum contractile activity
520. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat
521. Afferents originating from the dorsal penile nerve excite oxytocin cells in the hypothalamic paraventricular nucleus of the rat
522. Peptide histidine methionine (PHM) and the human male genitalia
523. Increases in intracavernous penile pressure following injections of excitatory amino acid receptor agonists in the hypothalamic paraventricular nucleus of anesthetized rats
524. Opposite influences of dopaminergic receptor subtypes on penile erection
525. Endothelin-1 as a putative modulator of erectile dysfuncton. II. Calcium mobilization in cultured human corporal smooth muscle cells
526. "On demand" erection with oral preparations for impotence: 3-(N-(2-imidazoline-2ylmethyl)-p-toluidinol) phenol mesylate
527. Experience with buccal phentolamine mesylate for impotence
528. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence
529. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction
530. Overall cardiovascular profile of sildenafil citrate
531. Nitric oxide mediated erectile activity is a testosterone dependent event: A rat erection model